TW202228682A - 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病 - Google Patents

使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病 Download PDF

Info

Publication number
TW202228682A
TW202228682A TW110137597A TW110137597A TW202228682A TW 202228682 A TW202228682 A TW 202228682A TW 110137597 A TW110137597 A TW 110137597A TW 110137597 A TW110137597 A TW 110137597A TW 202228682 A TW202228682 A TW 202228682A
Authority
TW
Taiwan
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
acceptable salt
administered
individual
Prior art date
Application number
TW110137597A
Other languages
English (en)
Chinese (zh)
Inventor
法蘭克 優卡
羅伯特 里辛格
維沃 麥可 德
弗里索 波斯塔瑪
Original Assignee
美商百歐克斯賽爾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐克斯賽爾治療公司 filed Critical 美商百歐克斯賽爾治療公司
Publication of TW202228682A publication Critical patent/TW202228682A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110137597A 2020-10-08 2021-10-08 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病 TW202228682A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08

Publications (1)

Publication Number Publication Date
TW202228682A true TW202228682A (zh) 2022-08-01

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110137597A TW202228682A (zh) 2020-10-08 2021-10-08 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes

Also Published As

Publication number Publication date
CN116615243A (zh) 2023-08-18
IL301971A (en) 2023-06-01
MX2023003993A (es) 2023-05-24
JP2023545372A (ja) 2023-10-30
CA3195133A1 (en) 2022-04-14
WO2022076818A1 (en) 2022-04-14
EP4225305A1 (en) 2023-08-16
US20240024289A1 (en) 2024-01-25
AU2021356687A9 (en) 2024-10-03
KR20230084186A (ko) 2023-06-12
EP4225305A4 (en) 2024-10-23
AU2021356687A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
US11497711B2 (en) Film formulations containing dexmedetomidine and methods of producing them
TW202228682A (zh) 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
US20250319069A1 (en) Methods for treating depressive states
AU2012241189A1 (en) Fast Dissolving Solid Dosage Form
CN117750956A (zh) 用于治疗抑郁状态的方法
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения